Dr. Bendell on the Future of Regorafenib for Patients With CRC

Johanna C. Bendell, MD
Published: Wednesday, Nov 15, 2017



Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

Further studies need to be done to determine the best dosage for regorafenib because most patients cannot tolerate the current dose, says Bendell.

A current trial conducted by researchers out of Mayo Clinic is comparing the full dosage to a lower dosage to see if tolerability will translate into increased progression-free survival, explains Bendell.


Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

Further studies need to be done to determine the best dosage for regorafenib because most patients cannot tolerate the current dose, says Bendell.

A current trial conducted by researchers out of Mayo Clinic is comparing the full dosage to a lower dosage to see if tolerability will translate into increased progression-free survival, explains Bendell.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x